Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a ...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% ...
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion ...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
A new report suggests patients with obesity and chronic spontaneous urticaria (CSU) tend to be older when diagnosed with the latter condition, and are also less likely to respond to omalizumab (Xolair ...
Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as 'DualityBio' or the ...
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer ...
This study characterized the pharmacokinetics of nafamostat and its effect on post-filter and systemic Activated Clotting Time (ACT) across different membrane types in a porcine model of AKI receiving ...
Context Therapeutics Inc. ("Context” or the "Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...
Science Translational Medicine Features GlyphAllo™: First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results